Loading...
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Woods, B Paracha, N Scott, D Thatcher, Nick
Woods, B
Paracha, N
Scott, D
Thatcher, Nick
Citations
Altmetric:
Abstract
The National Institute for Health and Clinical Excellence (NICE) has previously recommended pemetrexed plus cisplatin for the treatment of patients with advanced malignant pleural mesothelioma (MPM) and WHO performance status 0-1. Subsequent to this appraisal, randomised controlled trial (RCT) data for raltitrexed plus cisplatin and comparing chemotherapy to active symptom control (ASC) has become available, allowing a more complete analysis of the comparative efficacy and cost-effectiveness of first-line chemotherapy in MPM.
Authors
Description
Date
2012-02
Publisher
Collections
Keywords
Type
Article
Citation
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. 2012, 75 (2):261-7 Lung Cancer